Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read moreDr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read moreNew Clinical Trials Available at Texas Retina
At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical
read moreDr. Wang Invited to Serve as Guest Lecturer at Ohio State University
Texas Retina’s Robert C. Wang will speak at The Ohio State University’s 7th Annual Retina Case Forum on Friday, August 16, 2024, as an invited guest lecturer. The event is a case-based
read moreTexas Retina Recognizes Jennifer Hagger Ward for 26+ Years of Service
We continue to recognize Texas Retina team members who have served our practice for 20 years or more. Today, we are honoring Jennifer Hager Ward, who joined Texas Retina in 1997, and
read moreKimberly Jones Recognized for 26+ Years of Service to Texas Retina
We are continuing to celebrate our team members who have been a part of the Texas Retina family for 20 years or more. Today we recognize Kimberly Jones who joined our team
read moreCelebrating Sarah Yarletts’ 26+ Years of Service to Texas Retina
We continue to recognize Texas Retina team members who have served our practice for 20 years or more. Today, we honor Sarah Yarletts, who joined Texas Retina in 1997 and currently serves
read more